التفاصيل البيبلوغرافية
| العنوان: |
The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. |
| المؤلفون: |
Merz LE; Dana-Farber Cancer Institute, Boston., Fogerty AE; Massachusetts General Hospital, Boston. |
| المصدر: |
NEJM evidence [NEJM Evid] 2023 Feb; Vol. 2 (2), pp. EVIDe2200329. Date of Electronic Publication: 2023 Jan 24. |
| نوع المنشور: |
Editorial |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: NEJM Group, a division of the Massachusetts Medical Society Country of Publication: United States NLM ID: 9918317485806676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2766-5526 (Electronic) Linking ISSN: 27665526 NLM ISO Abbreviation: NEJM Evid Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: [Waltham, MA] : NEJM Group, a division of the Massachusetts Medical Society, [2022]- |
| مواضيع طبية MeSH: |
COVID-19* , Venous Thromboembolism* , Thrombosis*, Humans ; Anticoagulants/pharmacology ; SARS-CoV-2 ; Blood Coagulation |
| مستخلص: |
Thrombosis in patients with coronavirus disease 2019 (Covid-19) is driven by complex interactions between immune, complement, fibrinolytic, endothelial, and coagulation systems. 1 In addition to venous thromboembolism (VTE), microthrombi have also been implicated in contributing to end-organ damage, such as acute respiratory distress syndrome and kidney dysfunction, as well as to overall mortality. 1 As available therapies, variants, and vaccines have evolved, so have reported rates of VTE attributable to Covid-19. |
| المشرفين على المادة: |
0 (Anticoagulants) |
| تواريخ الأحداث: |
Date Created: 20240206 Date Completed: 20240208 Latest Revision: 20240208 |
| رمز التحديث: |
20240208 |
| DOI: |
10.1056/EVIDe2200329 |
| PMID: |
38320043 |
| قاعدة البيانات: |
MEDLINE |
